The findings, published in the journal Engineering, center on a compound called obakulactone (OL), a naturally occurring tetracyclic triterpenoid extracted from Phellodendri cortex, a type of plant bark. Tetracyclic triterpenoids are plant chemicals characterized by a structure containing four interconnected rings.

The researchers found that obakulactone helps restore balance to unsaturated fatty acids, which play important roles in cellular function and inflammation. It does this by promoting the breakdown of a protein called acyl coenzyme A thioesterase 1 (ACOT1), using the cell's natural protein disposal system, known as the ubiquitin‒proteasome pathway.

By identifying this previously underexplored molecular target, the study suggests that changing how cells process fatty acids could become a new strategy for treating rheumatoid arthritis (RA).

Natural Compound Reduces Arthritis Inflammation and Joint Damage

To investigate the compound's effects, scientists created a rat model of rheumatoid arthritis using complete Freund's adjuvant (CFA), a substance that triggers a strong inflammatory response resembling certain features of the disease.

The animals received obakulactone for 21 days at three different daily doses: low (50 mg·kg⁻¹·d⁻¹), medium (100 mg·kg⁻¹·d⁻¹), and high (200 mg·kg⁻¹·d⁻¹). These amounts were calculated according to body weight.

The results were encouraging. Rats treated with the compound experienced significantly less joint swelling, while the structure of their cartilage and synovium returned toward normal. The synovium is the thin membrane lining joints that produces lubricating fluid and can become severely inflamed in rheumatoid arthritis.

The treatment also improved disease-related changes in the thymus and spleen, two organs that play important roles in the immune system.

Beyond these physical improvements, researchers observed major changes in immune activity. Obakulactone reduced elevated levels of CD3⁺ T cells and CD68⁺ macrophages in joint tissues. These immune cells normally help defend the body, but they can contribute to persistent inflammation and tissue damage when the immune system becomes overactive.

The compound also shifted macrophages away from an inflammation-promoting M1 (CD86) state toward a more inflammation-resolving M2 (CD206) state. At the same time, it suppressed the development of CD4⁺ T cells into Th17 cells, a type of immune cell associated with autoimmune inflammation.

Blood tests provided further evidence of these effects. Obakulactone reduced several inflammatory signaling proteins, including IL-1β, IL-6, IL-17, and TNF-α. These proteins, known as cytokines, help immune cells communicate but can also intensify inflammation when produced in excessive amounts.

The treatment also lowered rheumatoid arthritis related blood markers, including rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (CCP-Ab), C-reactive protein (CRP), and matrix metalloproteinase-3 (MMP-3). The reductions became more pronounced as the dose increased.

Scientists Uncover a Surprising Link Between Fat Metabolism and Arthritis

One of the study's most intriguing findings involved fatty acids, molecules that are commonly associated with nutrition and energy storage but also influence inflammation throughout the body.

Using several advanced analytical methods, including metabolomics, MALDI mass spectrometry imaging, and proteomics, the researchers examined how obakulactone affected the chemical processes inside tissues.

These techniques allowed them to investigate changes in small molecules, map their distribution within tissues, and measure differences in protein levels.

The analysis revealed that the compound helped correct abnormalities in the production and breakdown of unsaturated fatty acids (e.g., arachidonic acid, linoleic acid, and α-linolenic acid).

These fatty acids are important components of cell membranes and can serve as raw materials for molecules that regulate inflammation. Arachidonic acid, in particular, is involved in producing several powerful inflammatory signals.

In the rats with arthritis, obakulactone helped bring these disrupted metabolic processes back toward a healthier balance. This suggested that its benefits extended beyond simply suppressing immune activity.

A Hidden Protein Emerges as a Potential Treatment Target

To understand exactly how the compound worked, the scientists conducted additional laboratory experiments involving rheumatoid arthritis synovial fibroblasts (SFs).

These cells help maintain the tissue lining the joints. However, in rheumatoid arthritis, they can become abnormally aggressive, multiplying excessively, releasing inflammatory substances, and contributing to cartilage damage and tissue scarring.

Obakulactone slowed the growth of these cells, reduced their production of inflammatory cytokines, and encouraged apoptosis, the controlled process through which the body eliminates unwanted or damaged cells.

The researchers then investigated which protein the compound was acting on directly.

Using cellular thermal shift assays, microscale thermophoresis, and surface plasmon resonance, they identified ACOT1 as a direct molecular target of obakulactone.

The binding measurements produced a dissociation constant (Kd) of (6.18 ± 0.26) μmol·L⁻¹ (analyzed by microscale thermophoresis (MST)) and (6.34 ± 0.38) μmol·L⁻¹ (analyzed by surface plasmon resonance (SPR)).

These closely matching results provided evidence that the compound physically interacts with ACOT1. A dissociation constant describes how strongly two molecules bind to one another, with lower values generally indicating tighter binding.

Importantly, obakulactone did more than bind to the protein. It promoted ACOT1's destruction through the ubiquitin‒proteasome system, a cellular mechanism that marks proteins for removal and breaks them down.

This process reduced the activity of several downstream mechanisms associated with inflammation and abnormal cell behavior.

How Targeting One Protein Can Disrupt Inflammation

When ACOT1 was broken down, levels of another enzyme called stearoyl-CoA desaturase-1 (SCD1) also decreased. This enzyme helps regulate the production of certain unsaturated fatty acids.

The changes subsequently suppressed two major cellular signaling networks: Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT).

These pathways act like internal communication systems, carrying signals that influence how cells grow, survive, and respond to their surroundings. When their activity becomes abnormal, they can contribute to inflammation and excessive tissue growth.

By interfering with these signals, obakulactone reduced inflammation and fibrosis, a process involving excessive buildup of scar-like connective tissue, in rheumatoid arthritis synovial fibroblasts.

Additional experiments, including rescue tests and studies using molecular inhibitors, strengthened the evidence that ACOT1 was central to these effects.

The researchers confirmed that the compound's ability to reduce inflammation, slow abnormal cell proliferation, and encourage apoptosis depended on its influence over ACOT1, the arachidonic acid pathway, and the downstream JAK-STAT/PI3K-AKT signaling pathways.

Together, the findings point to a potential way of disrupting the biological processes that sustain arthritis inflammation rather than focusing exclusively on suppressing immune responses.

A Potential New Direction for Rheumatoid Arthritis Treatment

Rheumatoid arthritis is a chronic autoimmune disease in which the immune system mistakenly attacks the body's own tissues, particularly the joints. It affects approximately 1% of people worldwide and can cause persistent pain, swelling, stiffness, and progressive joint damage.

Because it is a systemic disease, rheumatoid arthritis can also affect organs and tissues beyond the joints.

Although existing medications can reduce symptoms and slow disease progression, they do not work equally well for everyone, and some can cause serious side effects. This makes the search for additional treatment approaches especially important.

The new findings suggest that obakulactone could become a candidate for future rheumatoid arthritis drug development. They also identify ACOT1 as a potentially valuable treatment target and highlight the importance of unsaturated fatty acid metabolism in controlling inflammation.

However, the results remain preclinical. The compound has been tested in rats and laboratory cells, and additional research will be necessary to determine whether it is safe and effective in humans.

Even with that limitation, the discovery opens an intriguing possibility: targeting the metabolic machinery that helps drive inflammation could provide another way to combat rheumatoid arthritis and potentially protect joints from lasting damage.